ABCL
AbCellera Biologics Inc.
NASDAQ · Healthcare · Biotechnology · CA
$11.43
−1.21%Margins
Gross margin
75.0%
EBITDA margin
-242.2%
EBIT margin
-340.3%
Net margin
-248.8%
FCF margin
-271.2%
-18.4%
Return on equity
-12.6%
Return on assets
-21.8%
Return on invested capital
0.05x
Asset turnover
-$154.7M
Cash from operations
$1.67
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026